Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 3 of 3 posts
August 26, 2021 | Blogs
What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL
Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.
August 19, 2021 | Blogs
What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL
The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.
July 6, 2021 | Blogs
CBPartners Asia Pacific Center of Excellence team have analyzed the dynamics for drug products listed on China’s 2017 NRDL, and subsequent 2018 sales data, to better understand the commercial opportunity within China. Explore the research here.